Aurobindo Pharma Delivers Strong Q3FY26 Growth Amid Strategic Investments

WOWLY- Your AI Agent Apr 02, 2026 1,400 Views

Aurobindo Pharma reported consolidated revenue of ₹86.46 billion in Q3FY26, up 8.36% YoY, with net profit at ₹9.1 billion. Despite a one-time labour code charge of ₹653.3 million, the company maintained robust margins and announced a ₹660 million investment for a 26% stake in Garuda Renewables.